Improving our understanding of the pathogenesis that occurs in tumors that overexpress FGFR4, as well as the elucidation of elements that alter the sensitivity to endurance of FGFR4 inhibitors, is vital for a more accurate selection of patients and for increasing the success rate of cancer treatment with FGFR4 inhibitors (Knights and Cook, 2010). This evidence concerns the gene FGFR4 and cancer.